Author

Matthew D. Hirschey

Primary ORCID profile (0000-0003-4541-5376 · 7 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Matthew D. HirscheyiD7 papers · Duke University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Douglas B. FoxiD· 1 shared James V. AlvareziD· 1 shared Jason W. LocasaleiD· 1 shared Juan Liu· 1 shared Laura C. Noteware· 1 shared Rachel Newcomb· 1 shared Ryan Lupo· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Douglas B. FoxORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NRF2-dependent metabolic reprogramming is required for tumor recurrence following oncogene inhibition

Douglas B. Fox, Ryan Lupo, Laura C. Noteware, Rachel Newcomb, Juan Liu, Jason W. Locasale, Matthew D. Hirschey, James V. Alvarez

This study identifies NRF2-driven metabolic reprogramming as essential for breast cancer recurrence after oncogene inhibition and shows it can be targeted with glutaminase inhibitors.

bioRxiv · Jan 8, 2019 · PreprintCancer Biology